A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

Papillary thyroid carcinoma is the most common type of cancer to affect your thyroid-- a butterfly-shaped gland that sits just below your voice box. It's only about as big as a quarter ...

Of the three clinically distinct subtypes of intraductal papillary mucinous tumor (IPMT), those affecting only duct branches have been reported to have a better prognosis and to be less invasive ...

Background and Aim: Intraductal papillary mucinous tumor (IPMT) of the pancreas can be divided into three clinically distinct subtypes: main duct type, branch duct type and mixed type. Although it ...

Rather than tumor size alone, the American Thyroid Association’s risk stratification system should be used when assessing papillary thyroid microcarcinomas, according to data published in The Journal ...

The main supervisor is Ivan Shabo. My thesis is about prognostic factors in papillary thyroid cancer, which is the most common type of cancer in the thyroid gland. Today, treatment with surgery ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease. In Q2, the company submitted to the U.S. Food and Drug Administration (FDA) an Expanded ...

The chance of recovery, if you have this type, is good but slightly less than if you have papillary. This makes up about 4% of all thyroid cancer cases. If you have this kind, it’s likely to be ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...